265 filings
8-K
MBRX
Moleculin Biotech Inc
25 Apr 24
Regulation FD Disclosure
8:23am
8-K
MBRX
Moleculin Biotech Inc
18 Apr 24
Regulation FD Disclosure
8:30am
8-K
MBRX
Moleculin Biotech Inc
10 Apr 24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
8:30am
8-K
MBRX
Moleculin Biotech Inc
8 Apr 24
Other Events
5:14pm
8-K
MBRX
Moleculin Biotech Inc
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
9:05am
8-K
72b8hso2
25 Mar 24
Regulation FD Disclosure
3:03pm
8-K
ytn11wktx1
25 Mar 24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
7:30am
8-K
5uaqjg41fkwqvj 9s
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
8-K
99vpu5y2qdud c7sxt3
20 Mar 24
Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
7:30am
8-K
9sh6a1 hr
19 Mar 24
Moleculin Announces Reverse Stock Split
4:31pm
8-K
f0nsq1l6 5f0
29 Feb 24
Regulation FD Disclosure
8:30am
8-K
mo6ja
22 Feb 24
Regulation FD Disclosure
9:30am
8-K
10t zo3wz
15 Feb 24
Regulation FD Disclosure
9:15am
8-K
h7jhaxd
14 Feb 24
Regulation FD Disclosure
4:36pm
8-K
oupvqwbp1luzr16d0yx
14 Feb 24
Submission of Matters to a Vote of Security Holders
4:33pm
8-K
372ld
24 Jan 24
Regulation FD Disclosure
8:50am
8-K
jw0 htgc74cb1
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
awlz os28jc71xh
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
rvkboe2
18 Dec 23
Regulation FD Disclosure
8:55am
8-K
zqtw3oqpgsosb5w5
11 Dec 23
Regulation FD Disclosure
8:55am